Sleep Disorders

Recent research has identified novel potential pathophysiological mechanisms that could potentially serve to subclassify various phenotypes in obstructive sleep apnea.

The actimetry-based method allows for easily quantifiable sleep dynamics in real life context, enabling large-scale clinical studies to investigate the complex temporal dynamics of sleep.

Long-term maintenance of efficacy was demonstrated with solriamfetol for treatment of excessive sleepiness with narcolepsy or obstructive sleep apnea.

Neurology News Network for the week of September 28, 2018.

The neurologist and sleep specialist spoke about data from one of many studies investigating solriamfetol for treatment of narcolepsy and obstructive sleep apnea with remaining excessive daytime sleepiness.

Chylinski spoke about the relationship between the increased number of arousals during sleep and the pathogenesis of Alzheimer disease.

A pilot study has identified a potential link between obstructive sleep apnea and a higher risk of sudden unexpected death in epilepsy.

The restless leg syndrome expert discussed how general neurologists can best identify and address newly diagnosed patients, as well as what has changed in recent years.

The Johns Hopkins Associate Professor spoke about the current therapeutic landscape of restless leg syndrome, an often misdiagnosed disorder.

Patients with stroke should receive screening for sleep apnea in the short-term event period, receiving treatment with continuous positive airway pressure.

The RLS expert explained his best practices for treating patients who develop augmentation after treatment.

By the open-label extension’s end, those treated with pitolisant showed a decrease in ESS score by 6.2 from baseline.

Rachel Salas, MD, a Johns Hopkins Associate Professor, spoke about insomnia, a very individualized disorder, and the need for moving toward precision medicine.

The Johns Hopkins Associate Professor discussed the current of state sleep and also dove into the therapeutic landscape of sleep apnea.

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center spoke about the difficulties of treating sleepiness and what solriamfetol brings to the table.

Michael J. Thorpy, MBChB, spoke about solriamfetol’s success and the possibility of it treating other sleep conditions.

The senior lecturer in Clinical Pharmacy at Aston University talked about issues facing the medical community in treating those with dementia who have sleep problems.

The senior lecturer in Clinical Pharmacy at Aston University spoke about the findings of the ZED study, which looked into the use of hypnotic z-drugs.

The FDA has accepted a supplemental new drug application for sodium oxybate as a treatment for cataplexy and excessive daytime sleepiness in children with narcolepsy.

The results of a pair of trials of lemborexant support phase III findings of the investigational sleep-wake regulator.

The FDA has granted a Breakthrough Therapy and Fast Track Designation to pitolisant for cataplexy in patients with narcolepsy, as Harmony Biosciences prepares a new drug application for the drug.

The FDA has accepted an application for solriamfetol as a treatment for excessive sleepiness associated with narcolepsy or obstructive sleep apnea, with a PDUFA action date set for December 20, 2018.

The perception of good vibes and bad vibes is among the most difficult human experiences to define. The feeling that something “feels right” or that something “just isn’t right” has been attributed to multiple factors.

The encephalitis lethargica epidemic of 1916-1930 is estimated to have affected at least half a million of people in Europe and still remains a mystery.

What's the science behind predictive dreams?